We have some breaking news from Gilead.
The drugmaker was briefly halted in premarket trading and then released that remdesivir--its experimental drug--met a government study primary endpoint.
Remdesivir is being tested in multiple clinical trials and it is being used to treat severely ill COVID-19 patients who have been hospitalized.
The study is being conducted by the National Institute of Allergy and Infectious Diseases.
Remdesivir has been getting a slew of headlines--both good and bad--in the past couple of weeks.
Stat news reported positive findings based on a leaked video from a trial in Chicago on April 16 and then the World Health Organization accidentally posted a study on remdesivir from China, which reportedly showed that the drug wasn't helping to speed up the recovery of patients with COVID-19. Gilead had said, however, that the data noted a "potential benefit."
"These study results complement data from the placebo-controlled study of remdesivir conducted by the National Institute for Allergy and Infectious Diseases and help to determine the optimal duration of treatment with remdesivr," noted Merdad Parsey, Chief Medical Officer at Gilead.
The study demonstrates the potential for some patients to be treated with a 5-day regimen, which could significantly expand the number of patients who could be treated with our current supply of remdesivir," Parsey said.
Watch More of the Latest Videos from TheStreet and Jim Cramer
- Wednesday Coronavirus Update: The U.S. Surpasses One Million Cases Worldwide
- Google Beat on Top Line, Misses on Bottom: What's Driving the Stock
- Hot Dog Sales Remain a Home Run, Despite Zero Sporting Events
- Professional Athletes in Business: NBA Hall of Famer David Robinson Says Teamwork is Recipe for Success